In addition, vesicular monoamine transporter 2 (VMAT2) inhibitors, such as valbenazine and deutetrabenazine, have been approved for the treatment of TD and have shown efficacy in reducing involuntary movements [1-3]. This evidence concerns the gene SLC18A2 and thanatophoric dysplasia.